Identification of gene markers associated with aggressive meningioma by filtering across multiple sets of gene expression arrays

Journal of Neuropathology and Experimental Neurology

Volumn 70, Issue 1, 2011, Pages 1-12

  Stuart, Jourdan E ^a   Lusis, Eriks A ^a   Scheck, Adrienne C ^b   Coons, Stephen W ^b   Lal, Anita ^c   Perry, Arie ^a   Gutmann, David H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gene expression; Immunohistochemistry; Malignancy; Meningioma; Microarray; Quantitative RT PCR

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE 2; DNA TOPOISOMERASE; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL ALPHA SUBUNIT; LIVIN; PROTEINASE INHIBITOR; RIBONUCLEOTIDE REDUCTASE; TRANSCRIPTION FACTOR SOX11;

ADULT; AGED; ARTICLE; CANCER STAGING; CHILD; CONTROLLED STUDY; DLG7 GENE; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC MARKER; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MARKER GENE; MENINGIOMA; MICROARRAY ANALYSIS; NUSAP1 GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCHOOL CHILD; TIMP3 GENE; TPX2 GENE;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HUMANS; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM PROTEINS;

EID: 78650678164     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e3182018f1c     Document Type: Article

References (41)

1. CBTRUS: Statistical Report: Primary Brain Tumors in the United States, 1995-1999. Published by the Central Brain Tumor Registry of the United States, 2002
2. Perry A, Scheithauer BW, Stafford SL, et al. BMalignancy in meningi-omas: A clinicopathologic study of 116 patients, with grading implications. Cancer 1999;85:2046-56
3. Perry ALD, Scheithauer BW, Budka H, Von Deimling A. Meningiomas. In: WHO Classification of Tumours of the Central Nervous System. IARC: Lyon, France, 2007
4. Roser F, Nakamura M, Bellinzona M, et al. The prognostic value of progesterone receptor status in meningiomas. J Clin Pathol 2004;57: 1033-37
5. Perry A, Stafford SL, Scheithauer BW, et al. The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer 1998;82:2262-69
6. Martinez-Glez V, Franco-Hernandez C, Rey JA. Microarray gene expression profiling in meningiomas and schwannomas. Curr Med Chem 2008;15:826-33
7. Watson MA, Gutmann DH, Peterson K, et al. Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. Am J Pathol 2002;161:665-72
8. Tabernero MD, Maillo A, Gil-Bellosta CJ, et al. Gene expression profiles of meningiomas are associated with tumor cytogenetics and patient outcome. Brain Pathol 2009;19:409-20
9. Fevre-Montange M, Champier J, Durand A, et al. Microarray gene expression profiling in meningiomas: Differential expression according to grade or histopathological subtype. Int J Oncol 2009;35: 1395-407
10. Nutt CL, Mani DR, Betensky RA, et al. Gene expression-based classification of malignant gliomas correlates better with survival than his-tological classification. Cancer Res 2003;63:1602-7
11. Freije WA, Castro-Vargas FE, Fang Z, et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res 2004;64:6503-10
12. Carvalho LH, Smirnov I, Baia GS, et al. Molecular signatures define two main classes of meningiomas. Mol Cancer 2007;6:64
13. Lusis EA, Watson MA, Chicoine MR, et al. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res 2005;65: 7121-26
14. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001;98:5116-21
15. Hendricks W, Coons S, Preul M, et al. Global expression profiles predict meningioma recurrence and reveal novel pathways leading to aggressive phenotypes: A new clinical model of meningioma aggression. AACR Meeting Abstracts 2005;1:1149
16. Hendricks WP, Pfisterer W, Nieman R, et al. Characterization of molecular, genetic, and biochemical profiles associated with meningioma progression and recurrence. Society for Neuro-Oncology, Annual Meeting, 2004;6:337
17. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-8
18. Lusis EA, Chicoine MR, Perry A. High throughput screening of menin-gioma biomarkers using a tissue microarray. J Neurooncol 2005;73: 219-23
19. Korshunov A, Shishkina L, Golanov A. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: An analysis of 263 cases. Arch Pathol Lab Med 2002;126: 1079-86
20. Barski D, Wolter M, Reifenberger G, et al. Hypermethylation and tran-scriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas. Brain Pathol 2010;20: 623-31
21. Al-Khalaf HH, Lach B, Allam A, et al. Expression of survivin and p16(INK4a)/Cdk6/pRB proteins and induction of apoptosis in response to radiation and cisplatin in meningioma cells. Brain Res 2008;1188:25-34
22. Das A, Tan WL, Smith DR. Expression of the inhibitor of apoptosis protein survivin in benign meningiomas. Cancer Lett 2003;193:217-23
23. Sasaki T, Lopes MB, Hankins GR, et al. Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system. Acta Neuropathol 2002;104:105-9
24. Katoh M, Wilmotte R, Belkouch MC, et al. Survivin in brain tumors: An attractive target for immunotherapy. J Neurooncol 2003;64:71-76
25. Korshunov A, Shishkina L, Golanov A. Immunohistochemical analysis of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression in 271 meningiomas correlation with tumor grade and clinical outcome. Int J Cancer 2003;104:728-34
26. Konstantinidou AE, Patsouris E, Korkolopoulou P, et al. DNA topo-isomerase IIalpha expression correlates with cell proliferation but not with recurrence in intracranial meningiomas. Histopathology 2001;39: 402-8
27. Gu P, Xing X, Tanzer M, et al. Frequent loss of TIMP-3 expression in progression of esophageal and gastric adenocarcinomas. Neoplasia 2008; 10:563-72
28. Zhang K, Hu S, Wu J, et al. Overexpression of RRM2 decreases thrombospondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: Implication of RRM2 in angiogenesis. Mol Cancer 2009;8:11
29. Zhou B, Yen Y. Characterization of the human ribonucleotide reductase M2 subunit gene: Genomic structure and promoter analyses. Cytogenet Cell Genet 2001;95:52-59
30. Duxbury MS, Whang EE. RRM2 induces NF-kappaBYdependent MMP-9 activation and enhances cellular invasiveness. Biochem Biophys Res Commun 2007;354:190-96
31. Gruss OJ, Wittmann M, Yokoyama H, et al. Chromosome-induced microtubule assembly mediated by TPX2 is required for spindle formation in HeLa cells. Nat Cell Biol 2002;4:871-79
32. Shigeishi H, Ohta K, Hiraoka M, et al. Expression of TPX2 in salivary gland carcinomas. Oncol Rep 2009;21:341-44
33. Ma Y, Lin D, Sun W, et al. Expression of targeting protein for xklp2 associated with both malignant transformation of respiratory epithelium and progression of squamous cell lung cancer. Clin Cancer Res 2006;12: 1121-27
34. Moreau T, Baranger K, Dade S, et al. Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. Biochimie 2008;90:284-95
35. Saidi A, Javerzat S, Bellahcene A, et al. Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glio-blastoma. Int J Cancer 2008;122:2187-98
36. Gudmundsson KO, Thorsteinsson L, Sigurjonsson OE, et al. Gene expression analysis of hematopoietic progenitor cells identifies Dlg7 as a potential stem cell gene. Stem Cells 2007;25:1498-506
37. Ryu B, Kim DS, Deluca AM, et al. Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS One 2007;2:e594
38. Hyodo-Miura J, Urushiyama S, Nagai S, et al. Involvement of NLK and SOX11 in neural induction in Xenopus development. Genes Cells 2002;7: 487-96
39. Wurm A, Sock E, Fuchshofer R, et al. Anterior segment dysgenesis in the eyes of mice deficient for the high-mobility-group transcription factor SOX11. Exp Eye Res 2008;86:895-907
40. Lee CJ, Appleby VJ, Orme AT, et al. Differential expression of SOX4 and SOX11 in medulloblastoma. J Neurooncol 2002;57:201-14
41. Weigle B, Ebner R, Temme A, et al. Highly specific overexpression of the transcription factor SOX11 in human malignant gliomas. Oncol Rep 2005;13:139-44